Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. MD Anderson Cancer Center, Houston, TX, United States

Survival: 9.7 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Houston, TX
Hospital: MD Anderson Cancer Center
Journal: Link
Date: 7/2010

This phase II study involved 48 patients with first-relapse glioblastoma. The median age of the patients was 51 years (range 37-73). Gender distribution was not reported.

Patients in this study were treated with a biologic therapy called erlotinib (trade name Tarceva; made by Genentech, Inc.). Erlotinib is a small molecular inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in cell growth and survival.

One death related to treatment (due to sepsis) was reported in this study. Also, grade 3 or 4 diarrhea or rash was experienced by 4% and 18.8% of the patients, respectively.

Median overall survival in this study was 9.7 months.

This study was partially funded by Genentech, Inc., the makers of erlotinib.

Correspondence: Dr. W. K. Alfred Yung; email:

E-mail to a Friend Email Physician More Information